Pulmatrix Company Profile
Pulmatrix is discovering and developing a new class of therapies --inhaled cationic airway lining modulators (iCALM) –to prevent and treat respiratory infections and acute exacerbations of chronic respiratory diseases. iCALM therapies have broad potential to treat and prevent a wide range of respiratory diseases, including respiratory infections such as influenza; ventilator associated pneumonia (VAP) and respiratory syncytial virus (RSV), as well as progressive or chronic respiratory diseases such as COPD, asthma, and cystic fibrosis. For additional information about the Company, please visit http://www.pulmatrix.com.
News Articles
Pulmatrix Names Clarke CEO, Releases Promising Data on Lung Drug
Lexington, MA-based Pulmatrix, which is developing inhalable therapies for a variety of lung disorders, said today it is promoting chief scientific officer Robert Clarke to CEO. He will be replacing f...
Pulmatrix and CFFT partner to advance cystic fibrosis drug
Cystic Fibrosis Foundation Therapeutics and Pulmatrix agreed to work together to take the latter's PUR118, an inhaled drug ca -More-
Cystic Fibrosis Foundation Therapeutics and Pulmatrix Initiate Collaboration to Accelerate ...
$1.4 Million Award Will Advance Clinical Trials of Pulmatrix’s Lead iCALM™ Inhaled Drug Candidate in Cystic Fibrosis
Pulmatrix Presents Top Line Clinical Data Showing Inhaled Drug Candidate, PUR118, Demonstrated ...
Clinical Results from Lead Product Candidate Created from Pulmatrix’s Proprietary iSPERSE™ Inhaled Therapeutics Platform Three Presentations at European Respiratory Society Highli...
Pulmatrix, ImmuNext, ProThera, & More in Boston Life Sciences News
Life sciences companies across New England announced personnel moves, clinical trial updates, development deals, and funding this week. —Lexington, MA-based Pulmatrix announced it had promoted its c...
Pulmatrix, Cystic Fibrosis Foundation deal
Pulmatrix Appoints Robert Clarke, Ph.D., as Chief Executive Officer
Pulmatrix, a clinical stage biotechnology company creating novel inhaled therapeutics, today announced the appointment of Robert Clarke, Ph.D., as Chief Executive Officer....
Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALMâ„¢ therapeutic, the first...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Pulmatrix, Inc., is a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory...
Pulmatrix is discovering and developing a new class of therapies --inhaled cationic airway lining modulators (iCALM) –to prevent and treat respiratory infections and acute ex...
More Information about "Pulmatrix" on BioPortfolio
We have published hundreds of Pulmatrix news stories on BioPortfolio along with dozens of Pulmatrix Clinical Trials and PubMed Articles about Pulmatrix for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pulmatrix Companies in our database. You can also find out about relevant Pulmatrix Drugs and Medications on this site too.
